Navigation

neomycin/polymyxin B/bacitracin ophthalmic (Neo-Polycin)

 

Classes: Antibiotics, Ophthalmic Combos

Dosing and uses of Neo-Polycin (neomycin/polymyxin B/bacitracin ophthalmic)

 

Adult dosage forms and strengths

neomycin/polymyxin B/bacitracin ophthalmic

ophthalmic ointment

  • 400 units/3.5mg/10,000 units/g

 

Ocular Inflammation/Infection

Apply 1/2 inch ribbon of ointment to conjunctival sac of affected eye(s) q3-4hr for 7-10 days for acute infections

 

Pediatric dosage forms and strengths

neomycin/polymyxin B/bacitracin ophthalmic

ophthalmic ointment

  • 400 units/3.5mg/10,000 units/g

 

Ocular Inflammation/Infection

Apply 1/2 inch ribbon of ointment to conjunctival sac of affected eye(s) q3-4hr for 7-10 days for acute infections

 

Neo-Polycin (neomycin/polymyxin B/bacitracin ophthalmic) adverse (side) effects

Frequency not defined

Conjunctival edema

Rash

Allergic contact dermatitis

Itching

Failure to heaL

Swelling

Irritation

 

Warnings

Contraindications

Hypersensivity to neomycin, polymyxin B, zinc bacitracin

Glaucoma

Viral diseases of cornea and conjunctiva (epithelial herpes simplex keratitis, vaccinia, varicella)

Mycobacterial infection of eye & fungal diseases of ocular structures

 

Cautions

Contamination of container may occur, causing bacterial keratitis; avoid contamination of product

 

Pregnancy and lactation

Pregnancy category: C

Lacation: Excretion in breast milk unknown; caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Neo-Polycin (neomycin/polymyxin B/bacitracin ophthalmic)

Mechanism of action

Bacitracin: Inhibits bacterial cell wall synthesis by preventing the incorporation of amino acids and nucleotides into the cell walL

Neomycin: Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits

Polymyxin B: Bactericidal; causes leakage of bacterial membrane